The company
Nurix Therapeutics, Inc.
NRIX · Nasdaq
NRIX stood above a rising 150-day average in 47 of the last 52 weekly readings, including each of the last 19 weeks. It is 19.9% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 19 in a row
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $8.8M
- Officials’ trades on record
- 1
- Institutions holding
- 202 (+19)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 47 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
1 disclosed lines: House 0, Senate 0, executive 1; 1 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Eric S. Lander Executive branch: Office of Government EthicsOffice of Science and Technology Policy | sold | $50k–$100k | 16 Jun 2021filed 8 Sep 2021 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Gwenn HansenChief Scientific Officer | sold | 1,452at $25.00 | 15 Oct 2026filed 15 Oct 2026 |
| Julia P. GregoryDirector | sold | 22,583at $23.40 | 14 Oct 2026filed 14 Oct 2026 |
| Christine RingChief Legal Officer | sold | 5,786at $23.19 | 2 Oct 2026filed 2 Oct 2026 |
| Christine RingChief Legal Officer | sold | 5,387at $25.69 | 2 Sep 2026filed 2 Sep 2026 |
| Christine RingChief Legal Officer | sold | 400at $26.64 | 2 Sep 2026filed 2 Sep 2026 |
| Gwenn HansenChief Scientific Officer | sold | 1,452at $25.47 | 1 Sep 2026filed 1 Sep 2026 |
| Gwenn HansenChief Scientific Officer | sold | 4,356at $25.00 | 5 Aug 2026filed 5 Aug 2026 |
| Gwenn HansenChief Scientific Officer | sold | 1,500at $23.87 | 4 Aug 2026filed 5 Aug 2026 |
| Gwenn HansenChief Scientific Officer | sold | 2,611at $24.64 | 4 Aug 2026filed 5 Aug 2026 |
| Houte Hans VanChief Financial Officer | sold | 1,794at $23.89 | 4 Aug 2026filed 4 Aug 2026 |
| Houte Hans VanChief Financial Officer | sold | 2,967at $24.65 | 4 Aug 2026filed 4 Aug 2026 |
| Christine RingChief Legal Officer | sold | 16,589at $23.05 | 3 Aug 2026filed 3 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc.reduced · filed 7 Aug 2026 | 8,770,349$212.8M | -155,293−1.7% |
| Vestal Point Capital, LPadded · filed 14 Aug 2026 | 8,050,000$195.3M | +1,550,000+23.8% |
| Deep Track Capital, LPadded · filed 14 Aug 2026 | 7,736,455$187.7M | +1,391,211+21.9% |
| Rubric Capital Management LPadded · filed 14 Aug 2026 | 7,227,778$175.3M | +4,753,893+192.2% |
| FMR LLCreduced · filed 13 Aug 2026 | 5,485,215$133.1M | -56,056−1.0% |
| MORGAN STANLEYreduced · filed 13 Aug 2026 | 4,762,484$115.5M | -169,515−3.4% |
| STATE STREET CORPreduced · filed 7 Aug 2026 | 4,677,244$113.5M | -463,951−9.0% |
| BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 2026 | 4,658,556$113.0M | 00.0% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 4,495,529$109.1M | +68,417+1.5% |
| PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 2026 | 4,320,422$104.8M | +609,545+16.4% |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.